Key result
Review highlights novel pharmacological therapies across recent pivotal HF trials.
Why the study?
Heart failure remains a major global health burden, while the therapeutic landscape has evolved substantially driven by pivotal clinical trials across HFrEF, HFmrEF, and HFpEF.
This review provides a comprehensive update on recent pivotal clinical trials in heart failure, highlighting practice-changing implications and therapies shaping future guidelines.
Answers are grounded in this paper and cite their sources.
Informs clinicians of emerging HF therapies; leaves open their optimal guideline integration pending further trials.
Heart failure (HF) remains a major global health burden, with rising prevalence and significant morbidity and mortality despite advances in diagnosis and management. Over the past years, the therapeutic landscape of HF has evolved substantially, driven by a growing number of pivotal clinical trials addressing not only heart failure with reduced ejection fraction (HFrEF), but also heart failure with mildly reduced (HFmrEF) and preserved ejection fraction (HFpEF). The following review provides a comprehensive update on key clinical trials published or presented in the recent past such as DIGIT-HF, VICTORIA and VICTOR, STRONG-HF, SUMMIT or STEP-HFpEF trials, highlighting novel pharmacological therapies, patient phenotyping, and treatment of co-morbidities. Special attention is given to trials with practice changing implications and those shaping future guidelines.
No takes yet. Share an insight, caveat, or question.
Hoevelmann et al. (2025) conducted a review in Heart failure. Novel pharmacological therapies was evaluated. This comprehensive review highlights recent pivotal clinical trials in heart failure, including DIGIT-HF, VICTORIA, STRONG-HF, SUMMIT, and STEP-HFpEF, focusing on novel pharmacological therapies.
Synapse has enriched 10 related papers. Consider them for comparative context: